InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial



Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were enrolled and randomized (1:1:1) into three groups: orelabrutinib 75 mg once-daily (QD), orelabrutinib 50 mg QD, and placebo. Read More



Source link

  • Related Posts

    NASA Artemis II crew speaks on upcoming lunar launch

    IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing NASA Artemis II crew speaks on upcoming lunar launch 01:22 UP NEXT Officer…

    A 35-Year-Old Crypto Bro Helped Pakistan Win Over Trump World

    Plucked from relative obscurity last year, Saqib has suddenly become one of Pakistan’s most influential figures. He’s forged partnerships with crypto luminaries such as Changpeng Zhao, better known as CZ, the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    NASA Artemis II crew speaks on upcoming lunar launch

    NASA Artemis II crew speaks on upcoming lunar launch

    via Financial Post:

    A 35-Year-Old Crypto Bro Helped Pakistan Win Over Trump World

    The NDP has a new leader. What does Avi Lewis’s arrival mean for the party?

    The NDP has a new leader. What does Avi Lewis’s arrival mean for the party?

    Miles McBride cleared to play after missing last 28 games

    Miles McBride cleared to play after missing last 28 games

    Niecy Nash-Betts Goes Sky-high in Mirrored Louboutin Platform Sandals

    Niecy Nash-Betts Goes Sky-high in Mirrored Louboutin Platform Sandals